Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Targeting the sanctuary sites: Allogeneic CD19 CAR-T therapy for extramedullary relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Rui Liu, Jian Zhang, Qian Cheng, Fangping Chen, Rong He, Xin Li

Blood (2025) 146 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2025-1547

Published: 2025

Journal Articles

Construction and validation of a prediction model for extracorporeal circuit clotting risk during regional citrate anticoagulation in continuous renal replacement therapy for critically ill patients with hematological disorders

Jian Zhang, Xiaoying Wang, Jianxiong Hong, Yanan Feng, Bin Zhang, Jiajing Wang, Yijun Song

Blood (2025) 146 (Supplement 1): 6166.

https://doi.org/10.1182/blood-2025-6166

Published: 2025

Journal Articles

Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study

XIN CHEN, yuhan yan, Qian Cheng, yishu tang, ying Li, han xiao, erhua wang, jian zhang, Liwen Wang, qin zhang, Rong He, Fangping Chen, Xin Li

Blood (2025) 146 (Supplement 1): 3452.

https://doi.org/10.1182/blood-2025-3452

Published: 2025

Journal Articles

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

Abigail Yu, Wenyu Li, Zhili Zhou, Junjie Li, Charles Wang, Wei Ji, Ying Wang, Jian Zhang, Wei-Hong Cheng, Tian Zhang, Chihyi Hsieh, Alvin Luk, Vivien Zhang, David Sun, Yan Zhang

Blood (2025) 146 (Supplement 1): 3299.

https://doi.org/10.1182/blood-2025-3299

Published: 2025

Journal Articles

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, Quande Lin, Lihua Qiu, Zhiming Li, Wei Yang, Yuerong Shuang, Jian Zhang, Hongyan Tong, Hongmei Jing, Peiqi Zhao, Jing Liu, Hong Li, hongli zhang, Liqiang Fu, Gang Lu, Yuqin Song

Blood (2025) 146 (Supplement 1): 5368.

https://doi.org/10.1182/blood-2025-5368

Published: 2025

Journal Articles

Mortality-related risk factors associated with continuous renal replacement therapy in critically ill patients with hematologic disorders: A retrospective cohort study

Jiajing Wang, Xi Wang, Jian Zhang, Xiaoying Wang, Yijun Song

Blood (2025) 146 (Supplement 1): 7903.

https://doi.org/10.1182/blood-2025-7903

Published: 2025

Journal Articles

Filter coagulation related risk factors associated with continuous renal replacement therapy in critically ill patients with hematologic disorders: A retrospective cohort study

Jiajing Wang, Jian Zhang, Xiaoying Wang, Yijun Song

Blood (2025) 146 (Supplement 1): 7902.

https://doi.org/10.1182/blood-2025-7902

Published: 2025

Journal Articles

Linker Histone Regulates the Myeloid Versus Lymphoid Bifurcation of Multipotent Hematopoietic Stem and Progenitors

Shangqin Guo, Kutay Karatepe, Bruna Mafra De Faria, Jian Zhang, Xinyue Chen, Anna Eastman

Blood (2024) 144 (Supplement 1): 434.

https://doi.org/10.1182/blood-2024-211935

Published: 2024

Journal Articles

Efficacy and Safety of Venetoclax in Combination with Hypomethylating Agents for the Treatment of High-Risk Myelodysplastic Syndromes–Real-World Analyses

Jian Zhang, Yang Xu, Zhihong Lin, Jun Chen, Limin Liu, Depei Wu, Huiying Qiu

Blood (2024) 144 (Supplement 1): 6732.

https://doi.org/10.1182/blood-2024-199990

Published: 2024

Journal Articles

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Blood (2024) 144 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2024-192979

Published: 2024

Journal Articles

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Qian Cheng, JingWen Tan, Rui Liu, Liqing Kang, Hongjia Zhu, Yi Zhang, Erhua Wang, Ying Li, Jian Zhang, Han Xiao, Rong He, Xiaoyan Lou, Nan Xu, Wei Wang, Zhou Yu, Minghao Li, Hongfei Gu, Lei Yu, Xin Li

Blood (2024) 144 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2024-200516

Published: 2024

Journal Articles

Efficacy and Safety of Gilteritinib-Based Therapy Combinated with Allo-HSCT in Relapsed or Refractory Acute Myeloid Leukemia Patients with Positive FLT3-ITD Mutation

Jian Zhang, Yang Xu, Shengli Xue, Miao Miao, Ying Wang, Suning Chen, Depei Wu, Huiying Qiu

Blood (2024) 144 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2024-198895

Published: 2024

Journal Articles

Critical role of tripartite fusion and LBD truncation in certain RARA - and all RARG -related atypical APL

Blood (2024) 144 (14): 1471–1485.

https://doi.org/10.1182/blood.2024023883

Published: 2024

Includes: Supplemental data

Journal Articles

Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study

Jian Zhang, Baoquan Song, Yin Liu, De-Pei Wu, Huiying Qiu

Blood (2023) 142 (Supplement 1): 5947.

https://doi.org/10.1182/blood-2023-182665

Published: 2023

Journal Articles

Selinexor and Chidamide in Patients with Relapsed/Refractory Acute Myeloid Leukemia Exposed to Venetoclax: A Single-Arm, Phase 2 Study

Jian Zhang, Baoquan Song, Yin Liu, Yanjun Wu, De-Pei Wu, Huiying Qiu

Blood (2023) 142 (Supplement 1): 5950.

https://doi.org/10.1182/blood-2023-185770

Published: 2023

Journal Articles

Trinary Fusion with Ligand Binding Domain Castration Is Crucial in Rarg -Driven APL and Render Unresponsive to ATRA Via Allosteric Disability Mechanism

Blood (2023) 142 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2023-185483

Published: 2023

Journal Articles

Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)

Blood (2023) 142 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2023-178440

Published: 2023

Journal Articles

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Liqing Kang, Xiaowen Tang, Nan Xu, Minghao Li, Jingwen Tan, Wei Qi, Zhou Yu, Xiaoyan Lou, Shengli Xue, Xin Li, MD, Jian Zhang, MD, Jia Chen, MD, Zhenkun Wang, PhD, Caixia Li, Fu Cheng Cheng, MD PhD, Depei Wu, MD PhD, Lei Yu, MD PhD

Blood (2019) 134 (Supplement_1): 2621.

https://doi.org/10.1182/blood-2019-132067

Published: 2019

Journal Articles

The Lysine Histone Methyltransferase SETD2 Is Required for Appropriate Immunoglobulin VDJ Recombination

S. Haihua Chu, PhD, Jonathan Chabon, BS, Janna Minehart, BS, Chloe N Matovina, BS, Jian Zhang, Bo-Ruei Chen, PhD, Elsa Callen-Moreu, PhD, Putzer J Hung, Zhaohui Feng, BM, BS, Richard Koche, PhD, X. Shirley Liu, Jayanta Chaudhuri, Andre Nussenzweig, PhD, Barry Sleckman, Scott A. Armstrong, MD PhD

Blood (2018) 132 (Supplement 1): 511.

https://doi.org/10.1182/blood-2018-99-111952

Published: 2018

Journal Articles

Early Different Downstream Target of Glucocorticoid Receptor Contributing to Glucocorticoids Sensitivity in Kasumi-1 Cells

Wenbin Gu, Meng Li, Liang Liang, Jian Zhang, Chongye Guo, Zhikai Xing, Yongqing Lan, Sha Li, Yangyang Li, Ran Gao, Shuangli Mi

Blood (2016) 128 (22): 5132.

https://doi.org/10.1182/blood.V128.22.5132.5132

Published: 2016

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting the sanctuary sites: Allogeneic CD19 CAR-T therapy for extramedullary relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Construction and validation of a prediction model for extracorporeal circuit clotting risk during regional citrate anticoagulation in continuous renal replacement therapy for critically ill patients with hematological disorders

Genotype-guided comparison of ven-HMA versus intensive chemotherapy in newly diagnosed intermediate-risk AML: A multicenter real-world study

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Mortality-related risk factors associated with continuous renal replacement therapy in critically ill patients with hematologic disorders: A retrospective cohort study

Filter coagulation related risk factors associated with continuous renal replacement therapy in critically ill patients with hematologic disorders: A retrospective cohort study

Linker Histone Regulates the Myeloid Versus Lymphoid Bifurcation of Multipotent Hematopoietic Stem and Progenitors

Efficacy and Safety of Venetoclax in Combination with Hypomethylating Agents for the Treatment of High-Risk Myelodysplastic Syndromes–Real-World Analyses

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Long-Term Remission and Survival in Patients with Rituximab-Refractory/Relapsed B-Cell Non-Hodgkin Lymphoma after Treatment with U16 (CD20 CAR-T cells)

Efficacy and Safety of Gilteritinib-Based Therapy Combinated with Allo-HSCT in Relapsed or Refractory Acute Myeloid Leukemia Patients with Positive FLT3-ITD Mutation

Critical role of tripartite fusion and LBD truncation in certain RARA - and all RARG -related atypical APL

Selinexor in Combination with Hypomethylating Agent (HMA) in Patients with Refractory/Relapsed Acute Myeloid Leukemia (AML) Previously Exposed to Venetoclax: A Retrospective Study

Selinexor and Chidamide in Patients with Relapsed/Refractory Acute Myeloid Leukemia Exposed to Venetoclax: A Single-Arm, Phase 2 Study

Trinary Fusion with Ligand Binding Domain Castration Is Crucial in Rarg -Driven APL and Render Unresponsive to ATRA Via Allosteric Disability Mechanism

Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

The Lysine Histone Methyltransferase SETD2 Is Required for Appropriate Immunoglobulin VDJ Recombination

Early Different Downstream Target of Glucocorticoid Receptor Contributing to Glucocorticoids Sensitivity in Kasumi-1 Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only